We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Blog

IEX Chromatography Leading the Charge in Charge Variant Analysis
Blog

Find out how the biopharmaceutical industry has benefited from advances in chromatography technology, with insights from Matthew Lauber, consulting scientist at Waters.

Read More

Tailoring Flow Reactor Equipment to the Particular Chemistry at Hand
Blog

We recently spoke to André de Vries from InnoSyn BV to learn more about the considerations to make when scaling up chemical processes. He outlines the advantages of flow chemistry over batch processes and discusses how to design and manufacture flow reactors for any type of chemistry.

Read More

Take a Good Book Around
Blog

Our recent social media poll on "book recommendations for scientists" provided an incredible response. We decided to collate this information and give you the perfect excuse to treat yourself to a new read. Enjoy!

Read More

The Vision for Multi-organ Human-on-a-Chip Models
Blog

The development of organ-on-a-chip models aims to reduce the (expensive) high drug failure rates that exist in clinical trials. A Florida biotech firm recently reported that their multi-organ “human-on-a-chip” system maintains cellular viability over 28 days in serum-free conditions, using a pumpless system. To learn more about the vision for multi-organ “human-on-a-chip” models, we caught up with James Hickman, Chief Science Officer of Hesperos Inc.

Read More

Is Off-the-Shelf Immunotherapy the Way Forward?
Blog

An “off-the-shelf” immuno-oncology product has been developed whereby T cells are derived from healthy donors, bypassing limitations related to high pricing and limited market access.

Read More

The Booming Business of Neurotoxin Therapy
Blog

Botulinum neurotoxins are widely used in both therapeutic and cosmetic applications, but Ipsen says that their new rBoNT-E toxin is a step up from compounds based on the much more widely used serotype A toxin. We spoke to Ipsen Senior Vice President Neurosciences R&D, Philippe Picaut, to find out more.

Read More

Harnessing AI in a Battle Against Aging
Blog

A recently announced collaboration between Juvenescence, Ltd., and NetraMark Corp. has yielded a new joint venture, NetraPharma, which aims to fight aging-related conditions. We spoke with NetraMark founder Dr. Joseph Geraci to find out more about how the process of targeting and treating neurodegenerative disorders will be radically changed by AI.

Read More

Biosimilar Surge Driving Need for Antibody Characterization
Blog

Accurate protein characterization is particularly important in the biopharmaceutical industry, where product modifications can affect efficacy and safety. Here, we speak to Matthew Lauber, a consulting scientist who elaborates on the importance and challenges of biotherapeutic protein characterization, and discusses different techniques used for charge variant analysis.

Read More

Can We Treat Mood Disorders with Pharmacological Therapeutics?
Blog

Clinical treatments for neurological and mood disorders like social anxiety disorder and major depressive disorder have failed to show consistent efficacy in treating patients. VistaGen Therapeutics is aiming to correct that. We talked to VistaGen’s CEO, Shawn Singh, about the need for treatments in this area and why Vistagen thinks their compounds AV-101 and PH94B could be promising therapies.

Read More

Hybridoma vs Phage Display for Monoclonal Antibody Production
Blog

This blog highlights the key advantages and drawbacks of hybridoma development and phage display for a monoclonal antibody production in order to help you determine the best method for your needs.

Read More